Panel Discussion: PARPi’s: The Whole Story? PARP & DDR Biomarkers, Targets & Hope in Indications Outside of Breast & Ovarian
Time: 9:30 am
day: Day One
- Sharing insights into future directions and what to anticipate as standards evolve for PARP and other DDRi’s in the clinic
- How is it looking for prostate? leukemia? GBM? pancreatic? endometrial? SCLC?
- What are the differences between cancers in terms of resistance to PARP inhibitors?
- Thoughts on moving to a more genomic rather than indication-specific biomarker-driven treatment strategy?
- Understanding the hope for the more understudied PARP’s